A first Phase 2b study to investigate the safety and efficacy of the optimal dose range of PQ912 in early AD patients
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2017
At a glance
- Drugs PQ 912 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 30 Nov 2017 According to a Probiodrug media release, preparations of the trial have been initiated.
- 17 Oct 2017 New trial record
- 16 Oct 2017 According to a Probiodrug media release, Philip Scheltens will serve as the Prinacipal Investigator and Chairperson for this study. This trial is a part of the phase IIb core program starts which is planned to comprise of two complementary clinical Proof of Concept studies in Europe and the US.